Molecular Basis of Inhibitory Activities of Berberine against Pathogenic Enzymes in Alzheimer's Disease by Ji, Hong-Fang & Shen, Liang
The Scientiﬁc World Journal
Volume 2012, Article ID 823201, 4 pages
doi:10.1100/2012/823201 The  cientiﬁcWorldJOURNAL
Research Article
Molecular Basis of InhibitoryActivities of Berberineagainst
Pathogenic EnzymesinAlzheimer’sDisease
Hong-FangJi andLiangShen
Shandong Provincial Research Center for Bioinformatic Engineering and Technique, Shandong University of Technology,
Zibo 255049, China
Correspondence should be addressed to Liang Shen, shen@sdut.edu.cn
Received 27 October 2011; Accepted 16 November 2011
Academic Editor: Robert Perneczky
Copyright © 2012 H.-F. Ji and L. Shen.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The natural isoquinoline alkaloid berberine possesses potential to treat Alzheimer’s disease (AD) by targeting multiple pathogenic
factors. In the present study, docking simulations were performed to gain deeper insights into the molecular basis of berberine’s
inhibitory eﬀects against the important pathogenic enzymes of AD, that is, acetylcholinesterase, butyrylcholinesterase, and two
isoforms of monoamine oxidase. It was found that the theoretical binding aﬃnities of berberine to the four enzymes are very
close to the experimental values, which verify the methodology. Further inspection to the binding modes found that hydrophobic
interactions between the hydrophobic surface of berberine and neighboring hydrophobic residues are the principal forces
contributing to the ligand-receptor interactions. Although berberine cation also has potential to form electrostatic interaction
with neighboring residues, it is interesting to ﬁnd that electrostatic force is excluded in the four cases unexpectedly. These results
have important implications for the berberine-based anti-AD drug design.
1.Introduction
As a natural isoquinoline alkaloid isolated from the Chinese
herb Rhizoma coptidis, berberine (Figure 1) has gained con-
siderable attention because of its wide spectrum of biochem-
ical and pharmacological potentials, including antioxidant,
antiinﬂammatory, anticancer activities, and so forth, [1–
6]. Alzheimer’s disease (AD) is the most common form
of degenerative dementia with an estimated prevalence of
30 million people worldwide, and with the accelerated
aging of human society, its prevalence is expected to rise
steadily [7–10]. In recent years, multiple lines of evidence
support that berberine also possesses potential to act as
a multipotent agent to treat AD [11–14]. For instance,
many experimental studies reported that berberine exhibits
inhibitory eﬀects against several key enzymes implicated
in the pathogenesis of AD, including acetylcholinesterase
(AChE), butyrylcholinesterase (BChE), and monoamine
oxidase (MAO) [14–22]. With the aim to elucidate the
molecular basis of berberine’s inhibitory eﬀects against the
pathogenic enzymes in AD, in the present study, the binding
modes of berberine with four enzymes, that is, AChE,
BChE, MAO-A, and MAO-B, were investigated by means of
docking simulations. The results indicate that hydrophobic
interactions are the principal forces contributing to the
binding of berberine to the four enzymes. Despite the cation
ioninberberinestructure(Figure 1)caninteractreadilywith
the negatively charged acidic residues, no electrostatic force
is observed unexpectedly in the four cases. The ﬁndings
have important implications for the berberine-based anti-
AD drug design.
2. Methods
2.1. Structural Models. Structure coordinates for AChE,
BChE, MAO-A, and MAO-B were taken from the Protein
Data Bank (PDB codes: 1EA5 [23], 1P0I [24], 1O5W [25],
and 1GOS [26], resp.). The 3D structure of berberine
was ﬁrstly constructed using standard geometric parameters
of SYBYL software and then was optimized using Powell
method with the Tripos force ﬁeld (distance-dependent
dielectric) to reach a ﬁnal energy convergence gradient value
of 0.001kcal/mol.2 The Scientiﬁc World Journal
Figure 1: Chemical structure of berberine.
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Figure 2:Close-upviewsofbindingmodesofberberineinAChE(a),BChE(b),MAO-A(c),andMAO-B(d).Thehydrogenbondismarked
in green dotted lines.
2.2. Docking Methods. The Surﬂex-Dock program interfaced
with SYBYL software is employed to perform docking
experiments in this study, which uses an empirically derived
scoring function based on the binding aﬃnities of protein-
ligand complexes and on their X-ray structures [27]. As a
ﬂexible docking method, Surﬂex-Dock has been proven to
be eﬃc i e n ti nt r e a t i n gn u m e r o u sp r o t e i nr e c e p t o r s[ 27, 28].
The active sites for four targets were selected on the basis of
experimentally reported key residues, which play key roles
in their catalytic activities [23–26]. During the simulations,
the Kollman-all atom charges were assigned to protein
atoms using SYBYL software. For berberine molecule, 30
conformations were selected to dock with target in each
run. Standard parameters were used to estimate the binding
aﬃnity characterized by Surﬂex-Dock scores. Surﬂex-Dock
scores (total scores) are expressed in −log10(Kd) units to
represent binding aﬃnities [29, 30].
3. Results and Discussion
The theoretical binding constants of berberine to AChE,
BChE, MAO-A, and MAO-B are estimated and listed in
Table 1. It can be seen that berberine possesses inhibitory
activity against the four enzymes and the respective binding
aﬃnities vary largely. The theoretical Kd of berberine to
AChE (0.66µM), BChE (3.31µM), MAO-A (105.2µM),
and MAO-B (66.0µM) are very close to the experimental
values (Table 1), which verify the accuracy of the present
methodology. According to the theoretical Kd, the inhibitory
activity of berberine against AChE is the highest among theThe Scientiﬁc World Journal 3
Table 1: Theoretically estimated binding constants (Kd)o fb e r b e r -
ine with AChE, BChE, MAO-A, and MAO-B, and experimental
IC50.
Targets Theoretical Kd (µM) Experimental IC50 (µM)
AChE 0.66 0.44 [14], 0.58 [15], 0.37 [16]
BChE 3.31 3.44 [14]
MAO-A 105.2 126 [19]
MAO-B 66.0 98.2 [20], 98.4 [21]
four enzymes, which is in agreement with the experimental
results.
To elucidate the forces contributing to the binding aﬃn-
ity, the binding modes of berberine in AChE, BChE, MAO-
A, and MAO-B are shown in Figure 2. From the molecular
structure point of view, berberine has a large hydrophobic
surface and a cation ion, which is ideal for interacting with
the hydrophobic residues and the negatively charged acidic
residues (Figure 1). As shown in Figure 2, the neighboring
residues to berberine in the four enzymes are almost all
aromatic and/or hydrophobic amino acids. Therefore, these
residues can readily form hydrophobic interactions with the
hydrophobic surface of berberine. According to Figure 2,
there are eight hydrophobic residues (four phenylalanine,
three tyrosine, and one tryptophan) interacting with berber-
ine in AChE, while only six hydrophobic residues (one
phenylalanine, two tyrosine, two tryptophan, and one
isoleucine) with respect to the binding pocket in BChE. Also,
a hydrogen bond is formed between berberine and Tyr121 in
AChE (Figure 2), which will strengthen the binding aﬃnity
and enhance the inhibitory activity of berberine against
AChE. These two aspects may account for the relatively
stronger binding of berberine to AChE than BChE. In
addition, there are less hydrophobic residues involved in the
binding of berberine to MAO-A and MAO-B (Figure 2),
which results in their much lower binding aﬃnity.
Although berberine cation also has the potential to form
electrostatic interaction with neighboring residues in four
enzymes, it is interesting to ﬁnd that as no corresponding
negatively charged acidic residues exist at proper positions,
no electrostatic interaction is observed. Therefore, according
to the present results, the inhibitory activities of berberine
against four targets mainly arise from hydrophobic interac-
tions.
4. Conclusions
Inconclusion,thetheoreticallyestimatedbindingaﬃnitiesof
berberine to the four enzymes, AChE, BChE, MAO-A, and
MAO-B, are very close to the experimental values. Accord-
ing to the binding modes, the hydrophobic interactions
between berberine and surrounding hydrophobic residues
in the enzymes play predominant roles, while electrostatic
force is excluded in the binding of berberine to the four
targets. These ﬁndings shed lights on the molecular basis
of the inhibitory eﬀects of berberine against the enzymes
implicated in the pathogenesis of AD and will be helpful for
the berberine-based anti-AD drug design.
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